COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00118235
Recruitment Status : Completed
First Posted : July 11, 2005
Last Update Posted : June 17, 2014
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This phase II trial is studying how well giving cisplatin and irinotecan together with bevacizumab works in treating patients with extensive-stage small cell lung cancer. Drugs used in chemotherapy, such as cisplatin and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of small cell lung cancer by blocking blood flow to the tumor. Giving cisplatin and irinotecan together with bevacizumab may kill more tumor cells.

Condition or disease Intervention/treatment Phase
Extensive Stage Small Cell Lung Cancer Drug: cisplatin Drug: irinotecan hydrochloride Biological: bevacizumab Other: laboratory biomarker analysis Phase 2

Detailed Description:


I. To determine the percentage of patients with extensive stage small cell lung cancer treated with cisplatin, irinotecan and bevacizumab who live longer than 12 months.


I. To assess the response rate of patients treated with cisplatin, irinotecan and bevacizumab.

II. To evaluate the toxicity and tolerability of the combination of cisplatin, irinotecan and bevacizumab.

III. To determine the association between VEGF/KDR complex expression and VEGF plasma levels and tumor response.


Patients receive cisplatin IV over 60 minutes and irinotecan IV over 90 minutes on days 1 and 8. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for 3 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 72 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Cisplatin, Irinotecan and Bevacizumab (NSC# 704865) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase II Study
Study Start Date : December 2004
Actual Primary Completion Date : April 2007
Actual Study Completion Date : July 2011

Arm Intervention/treatment
Experimental: Treatment (cisplatin, irinotecan hydrochloride, bevacizumab)
Patients receive cisplatin IV over 60 minutes and irinotecan IV over 90 minutes on days 1 and 8. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Drug: cisplatin
Given IV
Other Names:
  • CACP
  • CDDP
  • CPDD
  • DDP

Drug: irinotecan hydrochloride
Given IV
Other Names:
  • Campto
  • Camptosar
  • CPT-11
  • irinotecan
  • U-101440E

Biological: bevacizumab
Given IV
Other Names:
  • anti-VEGF humanized monoclonal antibody
  • anti-VEGF monoclonal antibody
  • Avastin
  • rhuMAb VEGF

Other: laboratory biomarker analysis
Correlative studies

Primary Outcome Measures :
  1. Survival time [ Time Frame: The time beginning at randomization until death or last known follow-up, assessed up to 4 years ]
    Described using Kaplan-Meier curves.

  2. Failure-free survival [ Time Frame: The time between randomization and the occurrence of disease progression, or death, whichever comes first, assessed up to 4 years ]
    Described using Kaplan-Meier curves.

Secondary Outcome Measures :
  1. Frequency of toxicity, tabulated by the most severe occurrence [ Time Frame: Up to 4 years ]
    Graded using the NCI CTCAE version 3.0.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All patients must have histologically or cytologically documented small cell carcinoma of the bronchus
  • The extensive disease classification for this protocol includes all patients with disease sites not defined as limited stage; limited stage disease category includes patients with disease restricted to one hemithorax with regional lymph node metastases, including hilar, ipsilateral and contralateral mediastinal, and/or ipsilateral supraclavicular nodes; extensive stage patients are defined as those patients with extrathoracic metastases, malignant pleural effusion, bilateral or contralateral supraclavicular adenopathy or contralateral hilar adenopathy
  • Measurable or Non-measurable Disease
  • No prior chemotherapy or investigational therapy for SCLC
  • Radiation therapy must have been completed at least three weeks before initiation of protocol therapy
  • No major surgical procedure within 28 days prior to starting treatment and fully recovered
  • No minor surgical procedure (mediastinoscopy or core biopsy) within 7 days prior to starting treatment
  • ECOG performance status: 0-2
  • No "currently active" second malignancy other than non-melanoma skin cancers
  • No CNS metastases; patients with a history of CNS metastases will NOT be eligible even if they have completed a course of CNS radiotherapy; all patients will have a screening brain CT or MRI to rule out occult CNS metastases
  • No recent history of CVA (within 6 months)
  • No serious or non-healing wound ulcer or bone fracture
  • Patients with a history of significant bleeding episodes (e.g., hemoptysis, bleeding diathesis, upper or lower GI bleeding) are not eligible; patients with trace blood in the sputum ("blood tinged sputum") are eligible
  • No myocardial infarction or significant change in anginal pattern within one year or current congestive heart failure (NYHA Class 2 or higher)
  • Patients with a history of hypertension must be well controlled (< 150/90) on a stable regimen of anti-hypertensive therapy
  • No HIV-positive patients receiving combination anti-retroviral therapy because of possible pharmacokinetic interactions with the protocol treatment; (patients with immune deficiency are at an increased risk of lethal infections when treated with marrow-suppressive therapy)
  • No chronic daily treatment with aspirin (> 325 mg/day) or on non-steroidal antiinflammatory agents known to inhibit platelet function; no treatment with dipyridamole (Persantine), ticlopidine (Ticlid), clopidogrel (Plavix), cilostazol (Pletal), or other antiplatelet agents
  • No clinically significant peripheral neuropathy (grade >= 2)
  • No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
  • No treatment with therapeutic anticoagulation; prophylactic anticoagulation for central venous access devices is allowed provided requirements of INR < 1.5 and PTT < 1.2 x ULN are met; caution should be taken in treating patients with low dose heparin or low molecular weight heparin for DVT prophylaxis as there may be an increased bleeding risk with bevacizumab
  • No current and/or recent (within 1 month) use of a thrombolytic agent; low dose thrombolytic therapy for maintenance of central venous catheter is allowed
  • No clinically significant peripheral arterial disease
  • Non-pregnant and non-nursing; the effect of the combination of bevacizumab, cisplatin, and irinotecan on the fetus and infant is unknown
  • Granulocytes >= 1,500/μl
  • Platelets >= 100,000/μl
  • Serum Creatinine =< ULN
  • Total Bilirubin < 2.0 mg/dl
  • SGOT < 2 x ULN
  • INR < 1.5
  • PTT < 1.2 x ULN
  • Urine protein (dipstick) < 1+

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00118235

Layout table for location information
United States, Illinois
Cancer and Leukemia Group B
Chicago, Illinois, United States, 60606
United States, Rhode Island
Rhode Island Hospital
Providence, Rhode Island, United States, 02903
Sponsors and Collaborators
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Neal Ready Cancer and Leukemia Group B
Layout table for additonal information
Responsible Party: National Cancer Institute (NCI) Identifier: NCT00118235    
Other Study ID Numbers: NCI-2012-02815
NCI-2012-02815 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
CALGB-30306 ( Other Identifier: Cancer and Leukemia Group B )
CALGB-30306 ( Other Identifier: CTEP )
U10CA031946 ( U.S. NIH Grant/Contract )
P30CA014236 ( U.S. NIH Grant/Contract )
First Posted: July 11, 2005    Key Record Dates
Last Update Posted: June 17, 2014
Last Verified: December 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Small Cell Lung Carcinoma
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents, Immunological
Antibodies, Monoclonal
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Immunologic Factors
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action